Cancer care should be grounded in evidence, but it should not feel cold or automatic. Research helps us understand what information matters, what treatment may achieve, when referral is worth discussing, and how to keep quality of life central.
The studies and guidelines below do not replace an examination or a patient-specific plan. They explain the principles behind the conversations we have when a lump is found, a diagnosis is uncertain, surgery is being considered, or a family is weighing comfort against more intervention.
The 2026 AAHA Oncology Guidelines are helpful because they do not treat cancer work-up as a fixed checklist. They start from a practical idea: when cancer is suspected, the next step should identify the tumour, understand how far the problem may extend, or check whether the pet is well enough for the options being discussed.
For owners, that means good cancer care should not feel like doing every possible test. A useful test answers a question that matters: what type of tissue is this, is it behaving aggressively, has it reached lymph nodes or organs, would surgery be planned differently, would referral be worthwhile, or would the result change the comfort plan?
One of the most useful client-friendly ideas in the guidelines is the difference between grade and stage. Grade describes what the cancer looks like under the microscope and how aggressive the tissue appears. Stage describes how large or extensive the cancer is in the pet's body, including lymph nodes or distant spread.
Those two things can point in different directions. A small lump can still be biologically serious. A larger mass may still be mainly a local surgical problem. This is why pathology, lymph node assessment, imaging and blood tests are chosen according to the tumour type rather than by appearance alone.
AAHA's diagnostic guidance is very clear that feeling a lump or seeing it on imaging does not reliably tell us what it is. Fine needle aspirates can be a low-burden first step for many accessible lumps and lymph nodes, especially when they can identify inflammation, fatty tissue, cystic change, mast cell tumours, lymphoma or another round-cell tumour pattern.
The limitation is just as important. Cytology looks at cells, not the full tissue structure. Biopsy or histopathology after removal can provide tumour type, grade, mitotic activity, invasiveness and margin information. That is the information that often decides whether the next step is monitoring, wider surgery, staging, referral, chemotherapy, radiation, or comfort-focused care.
Start here if you have found a lump and need to decide whether monitoring, sampling, surgery or supportive care is the next step.
Understand the tests that help identify what a lump is and what the result can or cannot tell us.
Learn how examination, cytology, biopsy, imaging, lymph node checks and staging fit together.
Review how surgery, chemotherapy, referral, supportive care and palliative care may fit different goals.
Use this when the most important question is how your pet is feeling and whether the current plan is helping.
The main finding for owners is that cancer care should be deliberate rather than automatic. The guidelines support diagnosis with cytology or histopathology, selective staging based on the tumour type, and treatment goals that reflect the pet's health and the family's priorities. In practice, that means we should be able to explain why a test is being recommended and what decision it may change.
They also give a useful way to think about staging tests: prognostic, practical and pertinent. Prognostic means the result affects outlook or treatment. Practical means the plan leaves room for treatment, not only testing. Pertinent means the test looks where that cancer is most likely to spread.
Reference: AAHA tumour diagnostics and staging guidance.
Soft tissue sarcomas are a good example of why the first plan matters. The consensus report describes these tumours as locally invasive, often poorly defined at the edges, and strongly influenced by grade and surgical margins. Many are more likely to recur locally than to spread early, so careful assessment and margin planning before surgery can matter more than the lump's surface appearance.
For a suspected sarcoma, a small or calm-looking lump should not automatically be treated as simple. Sampling, planning the surgical approach, and sending tissue for histopathology can change whether surgery is likely to be complete and whether referral options should be discussed.
Reference: Frontiers in Veterinary Science consensus report.
This large retrospective study looked at dogs treated with surgery followed by definitive radiation therapy. Even in that advanced treatment setting, previous recurrence and later distant spread were associated with more local progression. That supports a practical message we often discuss with owners: local control is important, but the history of the lump and the whole-pet staging picture still matter.
This does not mean every dog with a soft tissue sarcoma needs radiation. It means pathology, recurrence history, tumour location, margins and staging help decide whether surgery alone is reasonable, whether referral treatment is worth discussing, or whether monitoring and comfort are more appropriate.
Reference: JAVMA soft tissue sarcoma study.
The treatment sections are useful because they frame treatment around goals rather than a single right answer. Surgery, chemotherapy, immunotherapy, radiation therapy or combinations may improve or extend quality of life and survival for some patients. The right option depends on the diagnosis, expected benefit, side effects, cost, travel, the pet's temperament and the family's capacity.
The follow-up guidance also matters after treatment. A new sign in a cancer patient is not always cancer progression: it may be recurrence, treatment toxicity, or an unrelated problem in an older pet. Rechecks should therefore be matched to tumour behaviour, grade, stage and treatment protocol, with ongoing communication rather than a one-time discharge from care.
Reference: AAHA therapeutic interventions guidance.
The palliative-care review is important because it treats comfort care as active medical care, not as giving up. It discusses quality-of-life assessment, pain control, appetite and nausea support, owner education and team communication. This fits the reality of cancer care: sometimes treatment is aimed at cure, sometimes at control, and sometimes at making the time left gentler.
Palliative care can begin early. A pet can receive symptom relief, medication adjustment, nutrition support, mobility help and family decision support while other treatment options are still being considered.
Reference: Veterinary Medicine International palliative care review.
The melanoma consensus guidelines show why cancer advice has to be tumour-specific. A diagnosis such as melanoma is not enough by itself. Location, size, local invasion, lymph node involvement and distant spread can change prognosis and treatment options. Oral melanoma in dogs, for example, is staged using tumour size, lymph node status and metastasis.
Two pets with the same broad cancer name may need very different conversations. One may need local surgery, another may need staging and referral discussion, and another may be best served by comfort-led care.
Reference: Frontiers melanoma consensus guidelines.
If you are reading research because your pet has a lump or cancer diagnosis, we can help translate the evidence into the practical choices in front of you: what to test, what to treat, what to monitor, and what comfort looks like.
Return to the main cancer care page for diagnosis, treatment, chemotherapy, referral and supportive care context.
Learn how lump removal is assessed, planned and followed up when surgery is part of the decision.
Cancer decisions often overlap with age, chronic disease, comfort, medication tolerance and family capacity.
